Growing pharma influence may affect regulatory future of combination products
This article was originally published in Clinica
Executive Summary
The medtech industry needs to be particularly aware of the impact that the growing trend in the development of drug/device combination products may have on its future as the drug lobby’s influence grows. That is the view of Shayesteh Fürst-Ladani, director of SFL Regulatory Affairs & Scientific Communication, a newly established consultancy based in Switzerland.